Keyword
0-9
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1001 | 14ｰ3-3 |
| 1002 | 3-D culture |
| 1003 | 4-HNE |
| 1004 | 5-FU |
| 1005 | 8-OH-Gua |
A
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1006 | AAV vector |
| 1007 | ABC transporter |
| 1008 | ABCG2 |
| 1009 | Acrylamide |
| 1010 | Actin |
| 1011 | Adenoma / adenocarcinoma |
| 1012 | Adenomatous polyposis coli |
| 1013 | Adenovirus |
| 1014 | Adenovirus vector |
| 1015 | Adipocyte |
| 1016 | Adjuvant therapy |
| 1017 | Aging |
| 1018 | Ah receptor |
| 1019 | Akt |
| 1020 | Alcohol |
| 1021 | Allogeneic transplantation |
| 1022 | Alpha 1 acid glycoprotein |
| 1023 | Alpha fetoprotein |
| 1024 | Alternative splicing |
| 1025 | AMF |
| 1026 | AML |
| 1027 | AMP-activated protein kinase |
| 1028 | Anchorage dependent growth |
| 1029 | Androgen |
| 1030 | Androgen receptor |
| 1031 | Aneuploidy |
| 1032 | Angiogenesis |
| 1033 | Angiogenesis inhibition |
| 1034 | Animal model |
| 1035 | Annexin |
| 1036 | Anthracycline |
| 1037 | Anti cancer drug |
| 1038 | Anti metabolight |
| 1039 | Antibody |
| 1040 | Antioxidants |
| 1041 | Antisense |
| 1042 | Antitumor activity |
| 1043 | Antitumor CTL |
| 1044 | Anti-tumor promoter |
| 1045 | AP-1 |
| 1046 | APC |
| 1047 | Apoptosis |
| 1048 | Apoptosis related gene |
| 1049 | ARF |
| 1050 | Arf6 |
| 1051 | Array CGH |
| 1052 | Arsenic |
| 1053 | Asbestos |
| 1054 | Ascorbic acid |
| 1055 | ASK1 |
| 1056 | ATL |
| 1057 | ATM |
| 1058 | Aurora kinase |
| 1059 | Autophagy |
| 1060 | Azoxymethane |
B
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1061 | Bacteria |
| 1062 | B-cell lymphoma |
| 1063 | BCG |
| 1064 | Bcl-2 |
| 1065 | Bcl-x |
| 1066 | Bcr-Abl |
| 1067 | Beta catenin |
| 1068 | BHP |
| 1069 | Bile |
| 1070 | Bile acid |
| 1071 | Biliary tract carcinoma |
| 1072 | Bim |
| 1073 | Bioinformatics |
| 1074 | Biomarker |
| 1075 | Biopsy |
| 1076 | Biostatistics |
| 1077 | Birth cohort |
| 1078 | Bispecific diabody |
| 1079 | Bladder |
| 1080 | Bladder cancer |
| 1081 | Blood flow |
| 1082 | BMI-1 |
| 1083 | BMP |
| 1084 | BNCT |
| 1085 | Body mass index |
| 1086 | Bone marrow |
| 1087 | Bone marrow transplantation |
| 1088 | Bone metastases |
| 1089 | BRAF |
| 1090 | Brain metastasis |
| 1091 | Brain tumor |
| 1092 | BRCA1/2 |
| 1093 | Breast cancer |
| 1094 | Bystander effect |
C
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1095 | Cachexia |
| 1096 | Cadherin |
| 1097 | CagA |
| 1098 | calcium channel |
| 1099 | Cancer Antigen |
| 1100 | cancer control |
| 1101 | Cancer gene panel test |
| 1102 | Cancer genetics |
| 1103 | Cancer prevention |
| 1104 | Cancer registry |
| 1105 | Cancer risk assessment |
| 1106 | cancer stem cell |
| 1107 | Cancer vaccine |
| 1108 | Cap43 |
| 1109 | CAR |
| 1110 | Carbohydrate antigen |
| 1111 | Carcinogen |
| 1112 | Carcinogenesis |
| 1113 | carcinosarcoma |
| 1114 | Case-control study |
| 1115 | Caspase |
| 1116 | catechin |
| 1117 | Cathepsin |
| 1118 | CD155 |
| 1119 | CD44 |
| 1120 | CD8 |
| 1121 | CD98 |
| 1122 | Cdk |
| 1123 | Cdx |
| 1124 | CEA |
| 1125 | Cell adhesion |
| 1126 | cell adhesion molecules |
| 1127 | Cell cycle |
| 1128 | Cell cycle arrest |
| 1129 | Cell cycle checkpoint |
| 1130 | Cell death |
| 1131 | Cell density |
| 1132 | Cell differentiation |
| 1133 | Cell line |
| 1134 | Cell migration /motility |
| 1135 | Cell polarity |
| 1136 | Cell therapy |
| 1137 | centromere protein |
| 1138 | Centrosome |
| 1139 | Cervical cancer |
| 1140 | CGH-array |
| 1141 | Chaperone |
| 1142 | Chemokine |
| 1143 | chemokine receptor |
| 1144 | Chemoprevention |
| 1145 | chemoradiotherapy |
| 1146 | Chemosensitivity |
| 1147 | Chemosensitivity prediction |
| 1148 | Chemotherapy |
| 1149 | chemotherapy-induced alopecia |
| 1150 | Cholangiocarcinoma |
| 1151 | Cholesterol |
| 1152 | chromatin immunoprecipitation |
| 1153 | Chromatin remodeling |
| 1154 | Chromosomal instability |
| 1155 | Chromosome |
| 1156 | Chromosome aberration |
| 1157 | Chromosome translocation |
| 1158 | Cisplatin |
| 1159 | C-kit |
| 1160 | Claudin |
| 1161 | Clinical trial |
| 1162 | Clock |
| 1163 | C-MET |
| 1164 | CML |
| 1165 | C-Myc |
| 1166 | cofilin |
| 1167 | Cohort study |
| 1168 | colon cancer |
| 1169 | Colon carcinogenesis |
| 1170 | colonic cancer |
| 1171 | Colorectal adenoma |
| 1172 | Colorectal cancer |
| 1173 | Combination effect |
| 1174 | Comprehensive genomic profiling test |
| 1175 | Computer simulation |
| 1176 | Connexin |
| 1177 | COX-2 |
| 1178 | CpG DNA |
| 1179 | CpG methylation |
| 1180 | CTL |
| 1181 | Curcumin |
| 1182 | Cyclin |
| 1183 | cytarabine |
| 1184 | Cytodiagnosis |
| 1185 | Cytokeratin |
| 1186 | Cytokine |
| 1187 | Cytotoxic activity |
D
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1188 | DDS |
| 1189 | Dedifferentiation |
| 1190 | Demethylation |
| 1191 | Dendritic cell |
| 1192 | Dendritic cell therapy |
| 1193 | Diabetes mellitus |
| 1194 | Diagnosis |
| 1195 | Dietary fat |
| 1196 | Differentiation |
| 1197 | DMBA |
| 1198 | DNA adduct |
| 1199 | DNA damage |
| 1200 | DNA methylation |
| 1201 | DNA methyltransferase-1 |
| 1202 | DNA microarray |
| 1203 | DNA mismatch repair |
| 1204 | DNA polymerase |
| 1205 | DNA repair |
| 1206 | DNA Replication |
| 1207 | DNA synthesis |
| 1208 | DNA tumor viruses |
| 1209 | DNA vaccine |
| 1210 | DNA-PK |
| 1211 | Double strand break |
| 1212 | Doxorubicin |
| 1213 | Drug discovery |
| 1214 | Drug resistance |
| 1215 | Drug response |
E
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1216 | E-cadherin |
| 1217 | E2F |
| 1218 | EBV |
| 1219 | Economic evaluation |
| 1220 | education |
| 1221 | EGF receptor |
| 1222 | Embryonic stem cell |
| 1223 | EMT |
| 1224 | Endocytosis |
| 1225 | Endometrial cancer |
| 1226 | Endoplasmic reticulum |
| 1227 | Endothelial cell |
| 1228 | Endothelin |
| 1229 | Eph/Eph receptor |
| 1230 | Epidemiology |
| 1231 | Epigenetics |
| 1232 | Epithelial Mesenchymal Transition |
| 1233 | EPR effect |
| 1234 | ER stress |
| 1235 | ErbB-2/ HER2 /Neu |
| 1236 | ERCC1 |
| 1237 | ERK |
| 1238 | Esophageal cancer |
| 1239 | Estrogen |
| 1240 | Estrogen receptor |
| 1241 | Ets |
| 1242 | EVI1 |
| 1243 | Ewing sarcoma |
| 1244 | EWS-Fli1 |
| 1245 | exercise training |
| 1246 | Exosome |
| 1247 | Extracellular vesicle |
| 1248 | EZH2 |
F
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1249 | FAK |
| 1250 | Familial cancer |
| 1251 | Fanconi Anemia |
| 1252 | Fatty acid |
| 1253 | F-box protein |
| 1254 | FGF |
| 1255 | Fibronectin |
| 1256 | FISH |
| 1257 | FLT |
| 1258 | Flt3Ligand |
| 1259 | Free radical |
| 1260 | FRET |
| 1261 | Fucosylated glycoforms |
| 1262 | Fusion |
G
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1263 | G protein |
| 1264 | G1 arrest |
| 1265 | GADD45 |
| 1266 | galectin-3 |
| 1267 | Gallbladder cancer |
| 1268 | gamma delta T cell |
| 1269 | Ganglioside |
| 1270 | Gastric cancer |
| 1271 | Gastric carcinogenesis |
| 1272 | Gastrointestinal cancer |
| 1273 | Gastrointestinal stromal tumor |
| 1274 | GATA |
| 1275 | G-CSF |
| 1276 | GDNF |
| 1277 | GEF |
| 1278 | gefitinib |
| 1279 | Gemcitabine |
| 1280 | Gene amplification |
| 1281 | Gene delivery |
| 1282 | Gene expression |
| 1283 | Gene regulation |
| 1284 | Gene therapy |
| 1285 | Genetic alteration |
| 1286 | Genetic diagnosis |
| 1287 | Genetic factor |
| 1288 | Genome |
| 1289 | genome imprinting |
| 1290 | Genomic instability |
| 1291 | Genomic medicine |
| 1292 | genomics |
| 1293 | genotoxicity test |
| 1294 | genotoxicity test |
| 1295 | Glioblastoma |
| 1296 | Glioma |
| 1297 | Glucose deprivation |
| 1298 | Glutathione |
| 1299 | Glutathione S-transferase |
| 1300 | Glycogen synthase kinase-3 |
| 1301 | Glycolysis |
| 1302 | glycosylation |
| 1303 | Glycosyltransferase |
| 1304 | Glypican3 |
| 1305 | Green fluorescent protein |
| 1306 | Green tea |
| 1307 | Growth factor |
| 1308 | Gynecologic cancer |
H
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1309 | H2AX |
| 1310 | HBV |
| 1311 | HCV |
| 1312 | HDAC |
| 1313 | HDAC inhibitor |
| 1314 | Head and neck cancer |
| 1315 | Heat shock protein |
| 1316 | Heavy ion |
| 1317 | Hedgehog |
| 1318 | Helicobacter pylori |
| 1319 | Hematological malignancy |
| 1320 | Hematopoietic stem cell |
| 1321 | Heparan sulfate |
| 1322 | Heparanase |
| 1323 | Hepatoblastoma |
| 1324 | Hepatocarcinogenesis |
| 1325 | Hepatocellular carcinoma |
| 1326 | HER2 |
| 1327 | Herpes virus |
| 1328 | Heterochromatin |
| 1329 | Heterogeneity |
| 1330 | HGF |
| 1331 | HIF-1 |
| 1332 | Hippo pathway |
| 1333 | Histone acetylation |
| 1334 | Histone modification |
| 1335 | HLA |
| 1336 | HLH transcription factor |
| 1337 | HMG-CoA reductase inhibitor |
| 1338 | HNPCC |
| 1339 | HnRNP |
| 1340 | Homologous recombination |
| 1341 | Hormonal therapy |
| 1342 | HPV |
| 1343 | hTERT |
| 1344 | HTLV-1 |
| 1345 | Humanized antibody |
| 1346 | Hyaluronan |
| 1347 | Hyperplasia |
| 1348 | Hyperthermia |
| 1349 | Hypoxia |
I
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1350 | IFN |
| 1351 | IGF |
| 1352 | IGF-1 |
| 1353 | IGF-I receptor |
| 1354 | IGFBP-3 |
| 1355 | Ikaros |
| 1356 | IKK |
| 1357 | IL-1 beta |
| 1358 | IL-10 |
| 1359 | IL-12 |
| 1360 | IL-17 |
| 1361 | IL-18 |
| 1362 | IL-2 |
| 1363 | IL-6 |
| 1364 | imaging |
| 1365 | Immune cell therapy |
| 1366 | Immune checkpoint inhibitor |
| 1367 | Immune response |
| 1368 | Immune suppression |
| 1369 | Immunohistochemistry |
| 1370 | Immunotherapy |
| 1371 | in vivo imaging |
| 1372 | Inflammation |
| 1373 | inhibitor |
| 1374 | Integrin |
| 1375 | Interferon |
| 1376 | intestinal immune system |
| 1377 | Intestinal metaplasia |
| 1378 | Intratumor heterogeneity |
| 1379 | Invasion |
| 1380 | iPS cell |
| 1381 | Irinotecan |
| 1382 | Isothiocyanate derivatives |
J
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1383 | JNK |
| 1384 | JAK-STAT pathway |
K
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1385 | Kinase |
| 1386 | KRAS |
L
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1387 | Lactobacillus casei |
| 1388 | Laminin |
| 1389 | Laparoscopic surgery |
| 1390 | Lectin |
| 1391 | Leukemia |
| 1392 | Leukemogenesis |
| 1393 | Life-style |
| 1394 | linoleic acid |
| 1395 | Liposome |
| 1396 | Liquid biopsy |
| 1397 | Liver |
| 1398 | Liver carcinogenesis |
| 1399 | Liver cirrhosis |
| 1400 | Liver metastasis |
| 1401 | LMP1 |
| 1402 | LOH |
| 1403 | L-Tryptophan |
| 1404 | lung |
| 1405 | lung adenocarcinoma |
| 1406 | Lung cancer |
| 1407 | Lung carcinogenesis |
| 1408 | Lung Metastasis |
| 1409 | Lymph node metastasis |
| 1410 | lymphoma |
| 1411 | Lymphomagenesis |
| 1412 | Lymphoproliferative disorders |
M
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1413 | Macrophage |
| 1414 | Malignant lymphoma |
| 1415 | MALT lymphoma |
| 1416 | Mammary tumor |
| 1417 | MAPK |
| 1418 | Marker |
| 1419 | Mass Spectrometry |
| 1420 | MDM2 |
| 1421 | MDR |
| 1422 | medical oncologist |
| 1423 | Melanocyte |
| 1424 | Melanoma |
| 1425 | MEN |
| 1426 | Menin |
| 1427 | Mesenchymal Stem Cell |
| 1428 | Mesothelioma |
| 1429 | Metabolic activation |
| 1430 | Metalloprotease |
| 1431 | Metastasis |
| 1432 | methionine depletion |
| 1433 | Methylation |
| 1434 | MGMT |
| 1435 | Microarray |
| 1436 | microenvironment |
| 1437 | Micrometastasis |
| 1438 | microRNA |
| 1439 | Microsatellite instability |
| 1440 | Microtubule-associated protein |
| 1441 | Microtubule-Depolymerizing Agents |
| 1442 | Mismatch repair |
| 1443 | Mitochondria |
| 1444 | mitomycin C |
| 1445 | Mitosis |
| 1446 | MKL1 |
| 1447 | MKP |
| 1448 | MLL |
| 1449 | MLPA |
| 1450 | MMP |
| 1451 | Molecular epidemiology |
| 1452 | Molecular pathology |
| 1453 | Molecular target |
| 1454 | Molecular target therapy |
| 1455 | Monoclonal antibody |
| 1456 | Monocyte |
| 1457 | mRNA |
| 1458 | MSI |
| 1459 | mta1 |
| 1460 | MUC |
| 1461 | Mucin |
| 1462 | Multidrug resistance |
| 1463 | Multiple myeloma |
| 1464 | Multistep carcinogenesis |
| 1465 | Mutagenesis |
| 1466 | Mutant Frequency |
| 1467 | Mutation |
| 1468 | MYCN |
| 1469 | Myelodysplastic syndrome |
| 1470 | MYH |
| 1471 | Myofibroblast |
N
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1472 | N-myc |
| 1473 | Nanomedicine |
| 1474 | Nasopharyngeal carcinoma |
| 1475 | Natural compounds |
| 1476 | Nectin |
| 1477 | Neoadjuvant chemotherapy |
| 1478 | Neoantigen |
| 1479 | Neuroblastoma |
| 1480 | Neuroendocrine |
| 1481 | Neutrophils |
| 1482 | NF-kB |
| 1483 | NF1 |
| 1484 | Nitrogen oxide |
| 1485 | Nitrogen oxide |
| 1486 | NK cell |
| 1487 | NK lymphoma |
| 1488 | NKT cell |
| 1489 | Non-coding RNA |
| 1490 | Notch |
| 1491 | Nox1 |
| 1492 | Noxa |
| 1493 | Nrf2 |
| 1494 | NSAID |
| 1495 | Nuclear receptor |
| 1496 | Nuclear transport |
| 1497 | Nutrient deprivation |
| 1498 | NY-ESO-1 |
O
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1499 | Obesity |
| 1500 | OGG1 |
| 1501 | Oncogene |
| 1502 | Oncologist Education |
| 1503 | Oncolytic virus |
| 1504 | Oral cancer |
| 1505 | Organiod |
| 1506 | Orthotopic implantation |
| 1507 | Osteosarcoma |
| 1508 | Ovarian cancer |
| 1509 | Oxaliplatin |
| 1510 | Oxidative DNA damage |
| 1511 | Oxidative stress |
| 1512 | Oxygen consumption |
P
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1513 | P16 |
| 1514 | P21 |
| 1515 | P27 |
| 1516 | p38 MAPK |
| 1517 | P53 |
| 1518 | P53 knockout mouse |
| 1519 | P53 related gene |
| 1520 | P57 |
| 1521 | p63 |
| 1522 | P73 |
| 1523 | P75NTR |
| 1524 | Paclitaxel |
| 1525 | pain |
| 1526 | Pancreas |
| 1527 | Pancreatic cancer |
| 1528 | Parg |
| 1529 | Parp |
| 1530 | Pathology |
| 1531 | PAX family genes |
| 1532 | Paxillin |
| 1533 | PDGF |
| 1534 | PDGFRA |
| 1535 | PDX (Patient-derived xenograft) |
| 1536 | PEDF |
| 1537 | pediatrics |
| 1538 | Peptide |
| 1539 | Perineural invasion |
| 1540 | Periostin |
| 1541 | Peritoneal dissemination |
| 1542 | Peroxisome proliferator |
| 1543 | Personalized medicine |
| 1544 | PET |
| 1545 | Pharmacogenomics |
| 1546 | Pharmacokinetics |
| 1547 | Phase I study |
| 1548 | phenotype |
| 1549 | PhIP |
| 1550 | Phosphorylation |
| 1551 | Photodynamic therapy |
| 1552 | Physical Activity |
| 1553 | PI3-kinase |
| 1554 | PKC |
| 1555 | Platinum drug |
| 1556 | pleura |
| 1557 | podoplanin/Aggrus |
| 1558 | poly-ADP-ribose |
| 1559 | Polyamine |
| 1560 | Polycomb |
| 1561 | Polymeric drugs |
| 1562 | Polymorphism |
| 1563 | Polyphenol |
| 1564 | Post-transcriptional regulation |
| 1565 | PP2A |
| 1566 | PPAR |
| 1567 | Precision medicine |
| 1568 | Prevention Study |
| 1569 | Progesterone receptor |
| 1570 | Prognosis |
| 1571 | Progression |
| 1572 | Prostaglandin |
| 1573 | Prostanoid Receptor |
| 1574 | Prostate |
| 1575 | Prostate cancer |
| 1576 | Protease |
| 1577 | Proteasome |
| 1578 | proteasome inhibitor |
| 1579 | Protein kinase |
| 1580 | Protein kinase inhibitor |
| 1581 | Protein Phosphatase |
| 1582 | protein tyrosine phosphatase |
| 1583 | Protein-protein interaction |
| 1584 | Proteomics |
| 1585 | psychooncology |
| 1586 | psycho-oncology |
| 1587 | PTEN |
| 1588 | PU1 |
Q
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1589 | QOL |
| 1590 | Quantitative real time PCR |
| 1591 | Quiescence |
R
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1592 | Rac |
| 1593 | Rad |
| 1594 | Radiation |
| 1595 | Radioimmunotherapy |
| 1596 | Radiosensitivity |
| 1597 | Raf |
| 1598 | RANKL |
| 1599 | Ras |
| 1600 | RAS-GAP |
| 1601 | RB |
| 1602 | RCAS1 |
| 1603 | Reactive nitrogen species |
| 1604 | Reactive oxygen species |
| 1605 | Real world data |
| 1606 | Receptor tyrosine kinase |
| 1607 | RECK |
| 1608 | Recurrence |
| 1609 | regeneration |
| 1610 | regulatory T cell |
| 1611 | Renal cell carcinoma |
| 1612 | Replicon |
| 1613 | Ret |
| 1614 | Retinoic acid |
| 1615 | RGD peptide |
| 1616 | rhabdomyosarcoma |
| 1617 | Rho |
| 1618 | RhoGDI |
| 1619 | Risk factor |
| 1620 | RNA |
| 1621 | RNA interference |
| 1622 | RNA synthesis inhibitor |
| 1623 | RNA-binding protein |
| 1624 | RNF43 |
| 1625 | RUNX |
S
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1626 | S-1 |
| 1627 | S100 |
| 1628 | SAGE |
| 1629 | Salivary gland tumor |
| 1630 | Sarcoma |
| 1631 | Screening |
| 1632 | Second Cancer |
| 1633 | segmental duplication |
| 1634 | Selectin |
| 1635 | Semaphorin |
| 1636 | Seminoma |
| 1637 | Senescence |
| 1638 | Sensitivity test |
| 1639 | Sentinel node |
| 1640 | Septin |
| 1641 | SEREX |
| 1642 | serum markers |
| 1643 | Serum pepsinogen |
| 1644 | Shp1 |
| 1645 | SHPS-1 |
| 1646 | Sialic acid |
| 1647 | Sialidase |
| 1648 | sialyltransferase |
| 1649 | Signal pathway |
| 1650 | Signal transduction |
| 1651 | SIRT2 |
| 1652 | sister chromatid separation |
| 1653 | Skp2 |
| 1654 | SLPI |
| 1655 | Smad |
| 1656 | Small cell carcinoma |
| 1657 | small interfering RNA |
| 1658 | Small-cell lung cancer |
| 1659 | S-methylcysteine |
| 1660 | Smoking |
| 1661 | Snail |
| 1662 | SNP |
| 1663 | Social support |
| 1664 | SOCS |
| 1665 | Soft tissue tumor |
| 1666 | Sonodynamic therapy |
| 1667 | Sp1 |
| 1668 | Splice-site |
| 1669 | spontaneous carcinogenesis |
| 1670 | Squamous cell carcinoma |
| 1671 | Src |
| 1672 | SSX |
| 1673 | STAT3 |
| 1674 | stem cell |
| 1675 | Steroid |
| 1676 | Stomach |
| 1677 | Stromal |
| 1678 | Suicide gene |
| 1679 | sulfatase |
| 1680 | Sulfotransferase |
| 1681 | SUMO-1 |
| 1682 | Surgical treatment |
| 1683 | Survival |
| 1684 | Survivin |
| 1685 | Susceptibility gene |
| 1686 | SV40 |
| 1687 | SWI SNF complex |
| 1688 | synovial sarcoma |
| 1689 | Systems Biology |
| 1690 | SYT-SSX |
T
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1691 | T cell |
| 1692 | Tamoxifen |
| 1693 | Tankyrase |
| 1694 | Targeting |
| 1695 | Tat |
| 1696 | Tax |
| 1697 | Taxan derivative |
| 1698 | TCF4 |
| 1699 | TEL ETV6 |
| 1700 | TEL-AML1 |
| 1701 | Telomerase |
| 1702 | Telomere |
| 1703 | Testicular cancer |
| 1704 | TFPI-2 |
| 1705 | TGF-beta |
| 1706 | Th1 |
| 1707 | Thioredoxin |
| 1708 | Thymidine phosphorylase |
| 1709 | Thymidylate synthase |
| 1710 | Thyroid |
| 1711 | Thyroid cancer |
| 1712 | tiling array |
| 1713 | TM4SF |
| 1714 | TNF |
| 1715 | Tob |
| 1716 | Toll-like receptor |
| 1717 | Tongue cancer |
| 1718 | Topoisomerase |
| 1719 | Toremifene |
| 1720 | TPA |
| 1721 | TRAIL |
| 1722 | Transcription |
| 1723 | Transcription coupled repair |
| 1724 | transcription factors |
| 1725 | Transfection |
| 1726 | transformation |
| 1727 | Transgenic mouse |
| 1728 | Transgenic rat |
| 1729 | translation |
| 1730 | translational research |
| 1731 | translesion DNA synthesis |
| 1732 | transplantation |
| 1733 | transporter |
| 1734 | treatment |
| 1735 | tryptase |
| 1736 | TSC |
| 1737 | TSC-22 |
| 1738 | TSLC1 |
| 1739 | Tuberous sclerosis gene |
| 1740 | tubulin |
| 1741 | Tumor antigen |
| 1742 | Tumor growth |
| 1743 | Tumor Immunity |
| 1744 | Tumor marker |
| 1745 | Tumor progression |
| 1746 | Tumor Selectivity |
| 1747 | Tumor suppressor activity |
| 1748 | Tumor suppressor gene |
| 1749 | Tumorigenicity |
| 1750 | Tyrosin phospholylation |
| 1751 | Tyrosine kinase |
| 1752 | Tyrosine kinase inhibitor |
U
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1753 | Ubiquitin |
| 1754 | Ulcerative colitis |
| 1755 | ultrasound |
| 1756 | UPR |
| 1757 | Uterine cancer |
| 1758 | UV |
V
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1759 | Vaccine |
| 1760 | Vasculature |
| 1761 | VEGF |
| 1762 | VEGF-C |
| 1763 | VEGF-D |
| 1764 | VEGFR2 |
| 1765 | VEGFR-3 |
| 1766 | VHL |
| 1767 | Vinorelbine |
| 1768 | Viral therapy |
| 1769 | Virus vector |
| 1770 | Vitamin D3 |
| 1771 | Vitamin K |
W
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1772 | Wee1 |
| 1773 | Wilms tumor |
| 1774 | Wnt |
| 1775 | Wnt-5a |
| 1776 | WT1 |
X
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1777 | Xenograft |
Y
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1778 | YB-1 |
Z
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keyword |
|---|---|
| 1779 | Zinc finger |